Cerveau Technologies partners with Lexeo Therapeutics for use of tau imaging agent
Click Here to Manage Email Alerts
Cerveau Technologies Inc. has announced a license agreement with Lexeo Therapeutics Inc. that will allow Lexeo to use an investigational imaging agent from Cerveau for the assessment of neurofibrillary tangles in the brain.
According to a Cerveau press release, [F-18]MK-6240 will be used in positron emission tomography scans to determine the status and progression of aggregated tau proteins, which are characteristic of several neurodegenerative diseases, including Alzheimer’s disease.
The companies’ collaboration will focus on using the imaging agent in Lexeo’s ongoing clinical trial for an investigational gene therapy candidate for APOE4-associated AD.
“Cerveau is pleased to be working with Lexeo to better understand tau PET’s utilization in supporting therapeutic trials,” Cerveau CEO Rick Hiatt said in the release. “The collaboration with Lexeo is another important step forward in our strategy of expanding our international network of key academic and pharmaceutical industry collaborators in order to help fight against neurodegenerative diseases.”